您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Meisoindigo
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Meisoindigo
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Meisoindigo图片
CAS NO:97207-47-1
包装与价格:
包装价格(元)
5mg电议
10mg电议
50mg电议
100mg电议

产品介绍
Meisoindigo (Dian III) 是靛玉红的衍生物,可在 G0/G1 期停止细胞周期并诱导原发性急性髓性白血病 (AML) 细胞凋亡。 Meisoindigo 表现出高抗肿瘤活性。
Cas No.97207-47-1
别名甲异靛; Dian III; N-Methylisoindigotin; Natura-α
化学名(3E)-1-methyl-3-(2-oxo-1H-indol-3-ylidene)indol-2-one
Canonical SMILESCN1C2=CC=CC=C2C(=C3C4=CC=CC=C4NC3=O)C1=O
分子式C17H12N2O2
分子量276.29
溶解度DMF: 16 mg/ml,DMF:PBS (pH 7.2) (1:4): 0.20 mg/ml,DMSO: 1 mg/ml
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Meisoindigo is a potential agent for acute myeloid leukemia [1].

Meisoindigo is a synthetic modification of indirubin. It has been used for chronic myeloid leukemia in China with less toxicity. In the in vitro assay, it can inhibit synthesis of DNA and RNA and the assembly of microtubules. It is also reported to have efficacy in acute myeloid leukemia. In the AML cell lines, HL-60, NB4 and U937, meisoindigo induces apoptosis in both caspase-dependent and -independent pathways. The effect induced by meisoindigo is likely mediated through the intrinsic mitochondrial pathway. Meisoindigo also induces cell cycle arrest with more cells in sub-G1 and G0/G1 phases and fewer cells in the S phase. Besides, meisoindigo is found to induce differentiation in HL-60 and NB4 cell lines. The expression of hTERT can be down-regulated by meisoindigo, which can enhance the anti-leukemic activity of chemotherapeutic agents. Moreover, meisoindigo shows a moderate anti-tumor efficacy in NOD/SCID mice injected with AML cells [1].

References:
[1] Lee CC, Lin CP, Lee YL, Wang GC, Cheng YC, Liu HE. Meisoindigo is a promising agent with in vitro and in vivo activity against human acute myeloid leukemia. Leuk Lymphoma. 2010 May;51(5):897-905.